Advertisement

Drugs in R&D

, Volume 17, Issue 1, pp 53–64 | Cite as

Salvia (Sage): A Review of its Potential Cognitive-Enhancing and Protective Effects

  • Adrian L. Lopresti
Open Access
Review Article
First Online:

Abstract

Genus Salvia, commonly known as sage, is the largest genus in the Lamiaceae family. It comprises many species traditionally used as brain-enhancing tonics. In vitro and animal studies have confirmed that several Salvia species contain a large array of active compounds that may enhance cognitive activity and protect against neurodegenerative disease. In this review, the active constituents in plants belonging to the genus Salvia are summarised, and their influence on pharmacodynamics pertinent to cognitive activity are detailed. In particular, the effects of plants belonging to the genus Salvia and their constituents on cognitive skills including memory, attention and learning are detailed. Their potential effects in dementia, including Alzheimer’s disease, are also examined. Completed human trials are summarised, and factors influencing the potency of Salvia plants are covered. Finally, directions for future research are proposed to enhance our understanding of the potential health benefits of Salvia plants.

Keywords

Caffeic Acid Ursolic Acid Rosmarinic Acid Tanshinones Carnosic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Key Points

Salvia plants and their constituents can influence several biological mechanisms associated with cognition including their effects on amyloid-β, cholinergic activity, neurotrophins, oxidative stress, inflammation and anxiolytic/antidepressant behaviours.

Several studies have confirmed the many Salvia species have promising, cognitive-enhancing effects in human adults.

Further research is required to examine the longer-term cognitive-enhancing effects of Salvia species on cognition, memory and the treatment of neurodegenerative diseases such as Alzheimer’s disease.

1 Introduction

Cognition refers to mental actions associated with acquiring knowledge. It encompasses processes associated with attention, memory, judgment and evaluation, reasoning, problem solving and decision making. Interest in herbal remedies as cognitive-enhancing agents (often referred to as nootropics) is on the increase with several promising compounds available, including curcumin, Ginkgo biloba and Bacopa monnieri. The genus Salvia (sage) is the largest genus of plants in the Lamiaceae family, comprising over 900 species distributed throughout the world. Common species include S. officinalis (common sage), S. miltiorrhiza (Chinese sage), S. lavandulaefolia (Spanish sage), S. fruticose (Greek sage), S. sclarea (clary sage) and S. hispanica (chia).

Salvia officinalis comes from the Latin word meaning ‘to heal’ and is widely used in both culinary and medicinal preparations. Many species of Salvia are native to Mediterranean Europe and have been traditionally used for the treatment of a range of problems including digestive and circulation disturbances, bronchitis, coughs, asthma, memory problems, angina, mouth and throat inflammation, depression and excessive sweating. Salvia plants are traditionally noted for their antioxidant effects and ability to enhance ‘head and brain’ function, improve memory, quicken the senses, and delay age-associated cognitive decline [1].

In this review, the active constituents in plants belonging to the genus Salvia are summarised, and their influence on pharmacodynamic activity pertinent to cognition are detailed. In particular, the effects of plants belonging to the genus Salvia and their constituents on cognitive skills including memory, attention and learning are detailed. Their potential effects in dementia, including Alzheimer’s disease, are also reviewed. Completed human trials are summarised, and factors influencing the potency of Salvia plants are covered. Finally, directions for future research are proposed to enhance our understanding of the potential health benefits of Salvia plants.

2 Active Constituents in Salvia Species

As detailed in Table 1, Salvia plants are a rich source of polyphenol compounds with over 160 identified polyphenols, comprising an array of phenolic acids and flavonoids. These phenolic compounds include caffeic acid and its derivatives, rosmarinic acid, salvianolic acids, sagecoumarin, lithospermic acids, sagernic acid, and yunnaneic acids. The most prevalent flavonoids include luteolin, apigenin, hispidulin, kaempferol and quercetin [2]. Plants of the genus Salvia are also rich in essential oils, with a large array of terpenoids including α and β-thujone, camphor, 1,8-cineole, α-humulene, β-caryophyllene and viridiflorol. Moreover, they are rich sources of diterpenes and triterpenes such as carnosic acid, ursolic acid, carnosol and tanshinones.
Table 1

Common compounds identified in Salvia species

Phenolic acids

Caffeic acid, rosmarinic acid, salvianolic acids, sagecoumarin, lithospermic acid, sagerinic acid, yunnaneic acids

Flavonoids

Luteolin, apigenin, hispidulin, kaempferol, quercetin

Terpenoids

α and β-Thujone, camphor, 1,8-cineole, α-humulene, β-caryophyllene, viridiflorol, carnosic acid, ursolic acid, carnosol, tanshinones

Polysaccharides

Arabinogalactans, pectin

The composition of the polyphenols and terpenoids can vary considerably across Salvia species. For example, rosmarinic acid is high in S. officinalis but low in S. hypoleuka [3]. Levels of thujone are also reported to be higher in S. officinalis compared with S. lavandulaefolia [4]. Tanshinones are found in S. miltiorrhiza [5], and varying forms of yunnaneic acids and salvianolic acids differ across Salvia species.

3 Salvia and its Pharmacodynamic Influences on the Brain

Cognitive activity and performance can be influenced by an array of neurological and biochemical factors. Damage to specific neurological structures can be associated with specific cognitive deficits, and there is an increasing awareness of the influence of different hormones and neurotransmitters on cognitive activity. Because of its rich array of chemical constituents, plants of genus Salvia can influence multiple physiological pathways (summarised in Fig. 1). Those especially pertinent to cognition are summarised in the following sections.

3.1 Salvia and Amyloid-β

The accumulation of the amyloid-β peptide (Aβ) is a characteristic of Alzheimer’s disease and its deposition is considered partially responsible for the cognitive dysfunction seen in Alzheimer’s disease. It is theorised that aggregated Aβ is accountable for the progressive nature of the disease, as the unregulated build-up of aggregates are neurotoxic, causing dysfunction to cholinergic neurons and calcium homeostasis, and promoting the formation of reactive oxygen species (ROS) and pro-inflammatory responses. Aβ are known to cause specific learning and memory impairment and its administration has been renowned for inducing memory loss in animal models [6].

Salvia miltiorrhiza has been shown to protect mice from Aβ-induced neurotoxicity by inhibiting increases in tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) levels and acetylcholinesterase (AChE) activity [7]. Tanshinones from S. miltiorrhiza can also protect against Aβ-induced toxicity by ameliorating mRNA expression of inducible nitric oxide synthase (iNOS), matrix metalloproteinase 2 and nuclear transcription factor-κ [8].

Animal studies have demonstrated that supplementation with S. sahendica attenuated memory deficits, modulated cAMP response element binding protein and its down-stream molecules and decreased apoptosis in Aβ-injected rats [9]. In mice exposed to an acute injection of Aβ, rosmarinic acid also prevented Aβ-induced nitration of proteins (an indirect indicator of peroxynitrite damage) in the hippocampus. Rosmarinic acid also prevented memory impairments induced by Aβ toxicity [10]. Protective effects from Aβ toxicity have also been observed following the administration of the Salvia constituents, salvianolic acid [11], carnosic acid [12] and quercetin [13].

3.2 Salvia and Cholinergic Activity

Central cholinergic signalling has long been associated with features of memory, motivation and mood. Acetylcholine (ACh), a neurotransmitter involved in cholinergic signalling, is believed to play an important role in several aspects of cognitive function and behaviour, including attention, learning, memory and motivation. Alterations in ACh signalling are involved in the pathophysiology of multiple neurodegenerative disorders including Alzheimer’s disease [14]. Recent studies have also provided support for a role of cortical ACh in attentional effort, orientation and the detection of behaviourally significant stimuli [15].

AChE is an enzyme that catalyses the breakdown of acetylcholine and there are several AChE inhibitor drugs available to increase overall ACh concentration. These drugs are based on the premise that increasing the availability of ACh at acetylcholine receptors in the brain enhances neuron-to-neuron transport and ultimately improves cognitive function [16].

In vitro and animal studies have revealed that several Salvia species and their constituents are effective AChE inhibitors. An aqueous extract of S. officinalis lowered AChE activity in mice [17], and in vitro analyses revealed that ethanolic extracts of S. officinalis reduced AChE, with greater effects on butyrylcholinesterase [18, 19]. In mice subjected to Aβ peptide, pre-treatment with S. sahendica significantly ameliorated reductions in AChE activity and memory performance [20]. The essential oil of S. fruticosa also showed inhibition against AChE [21], and similar findings were revealed from the essential oil of S. lavandulaefolia, although AChE inhibiting activity occurred exclusively via the monoterpernoids [22]. AChE inhibition has also been observed from the phenolic diterpenes, 7a-methoxyrosmanol and isorosmanol, isolated from S. officinalis. [23]. The active constituents, rosmarinic acid, carnosic acid and quercetin, found in several Salvia species can also inhibit AChE activity [23, 24, 25]. The tanshinones from S. miltiorrhiza also inhibit both AChE and butyrylcholinesterase activity [26, 27].

3.3 Salvia and Neurotrophins

Neurotrophins are important regulators of neural survival, development, function and plasticity [28]. Brain-derived neurotrophic factor (BDNF) is one neutrophin that has received particular attention in cognitive and neurological research due to its role in supporting the survival of existing neurons, encouraging the growth and differentiation of new neurons and synapses, and enhancing learning and memory [29]. In a recent meta-analysis, peripheral BDNF levels were confirmed to be lower in patients with Alzheimer’s disease and mild cognitive impairment [30].

In one study, the administration of S. miltiorrhiza to mice mitigated Aβ-induced reductions in BDNF [7]. Rosmarinic acid also protected against memory deficits induced by cerebral artery occlusion in mice. One mechanism of the neuroprotective effects of rosmarinic acid involved an increase in BDNF [31]. In rats exposed to chronic unpredictable stress, rosmarinic acid restored hippocampal BDNF. Moreover, in vitro experiments revealed that rosmarinic acid increased BDNF levels in cultured astrocytes [32].

Caffeic acid reduced immobility time of mice in the forced swim test and ameliorated stress-induced reductions in levels of BDNF mRNA in the frontal cortex. Caffeic acid did not modify the levels of BDNF in brain regions of naive mice, indicating that it primarily attenuates the down-regulation of BDNF transcription during stressful conditions [33].

The flavonoid luteolin was identified to be highly active in inducing the synthesis and secretion of neurotrophic factors, including nerve growth factor, glial-derived neurotrophic factor and BDNF in cultured astrocytes [34]. There have also been some reports that quercetin can increase BDNF levels in brain injury models [35]. The production of nerve growth factor, another neurotrophin important for the growth, maintenance and survival of neurons, has also been shown to be enhanced by carnosic acid, carnosol [36], tanshinones [37] and quercetin [38].

3.4 Salvia and Antioxidant Effects

Excess free radical activity and reduced antioxidant defences create a state of oxidative stress. Over time, oxidative stress can damage all body tissues, with the brain particularly susceptible. Oxidative stress has been implicated in many neurological disorders including Alzheimer’s disease [39] and Parkinson’s disease [40]. Oxidative stress is also elevated in many mental health disorders including major depressive disorder [41] and attention-deficit hyperactivity disorder (ADHD) [42]. Moreover, animal models of induced oxidative stress have confirmed that it can adversely influence memory and learning performance [43, 44].

Salvia plants and their individual constituents possess strong antioxidant activity. In an analysis of 10 Salvia species, it was confirmed that all species exhibited significant antioxidant activity as measured by oxygen radical absorbance capacity, radical scavenging capacity and total phenolic content. The extent of antioxidant activity varied across species and extraction methods used, the ethanolic extract of S. officinalis exhibited the highest activity [45].

It has been confirmed that S. miltiorrhiza can reduce the production of ROS by inhibiting oxidases, reducing the production of superoxide, inhibiting the oxidative modification of low-density lipoproteins and ameliorating mitochondrial oxidative stress. S. miltiorrhiza also increases the activities of catalase, manganese superoxide dismutase, glutathione peroxidase, and coupled endothelial nitric oxide synthase [46]. In an animal model, S. officinalis prevented diabetes-induced acquisition and memory deficits by inhibiting lipid peroxidation and enhancing antioxidant defence systems [47].

The majority of antioxidant effects are attributed to Salvia phenolic compounds such as rosmarinic acid, salvianolic acid, sagecoumarin and sagerinic acid as they exhibit strong radical scavenging activity with approximately 90% of 2,2-diphenylpicrylhydrazyl (DPPH) scavenged under the experimental conditions. In fact, their effects were substantially greater than the sage flavonoids, luteolin and apigenin [48]. In another in vitro study, salvianolic acid L showed potent free radical scavenging activities for DPPH and superoxide anion radicals. It was identified as a significantly better scavenger of these free radicals than trolox (a water-soluble analogue of vitamin E), caffeic acid and rosmarinic acid [49].

The monoterpenes 1,8-cineole and α-pinene identified in S. lavandulaefolia essential oil were also able to attenuate oxidative injury in astrocytes by inhibiting ROS production and increasing endogenous antioxidant compounds (e.g. glutathione, catalase, superoxide dismutase, heme oxygenase 1 activity and protein expression) [50]. Carnosic acid and ursolic acid are also powerful antioxidants [51, 52].

3.5 Salvia and Anti-Inflammatory Effects

Evidence for the influence of inflammation on cognitive function is accumulating. In animal models, the activation of the immune system with lipopolysaccharides (LPS) [44], a high-fat diet [53] or the non-invasive enteric pathogen, Citrobacter rodentium [54], induced memory impairments. In a meta-analysis, it was confirmed that an elevated level of C-reactive protein was associated with a 45% increased risk of all-cause dementia, and a higher level of IL-6 was associated with a 32% increased risk. In patients with Alzheimer’s disease, the association remained significant but less pronounced for C-reactive protein, while there was no association with IL-6 [55]. However, in a meta-analysis on studies in people with mild cognitive impairment, no significant differences in inflammatory factors with healthy controls were identified [56]. Increased inflammation has been demonstrated in patients with ADHD [57], and increased inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder [58], and reduced cognitive performance in adults suffering from acute-phase psychosis [59].

Findings from in vitro and animal studies have demonstrated that Salvia species and their constituents have anti-inflammatory effects. An examination of the essential oils in S. officinalis (mainly comprising 1,8-cineole and camphor) revealed that it significantly inhibited nitric oxide production stimulated by LPS in mouse macrophages [60]. Acute inflammation induced with intraperitoneal administration of turpentine oil in mice was significantly reduced by S. officinalis tincture, demonstrated by reductions in total leukocyte and monocyte percentages, and the activation of circulating phagocytes [61]. Phenolic diterpenes (carnosol and carnosic acid) present in S. officinalis reduced nitric oxide and prostaglandin E2 (PGE2) production in LPS-stimulated macrophages. They also significantly blunted gene expression levels of iNOS, cytokines/interleukins (IL-1α, IL-6) and chemokines including CCL5/RANTES and CXCL10/IP-10 [62].

A methalonic extract of S. plebeian, and several of its active components, significantly reduced inflammatory processes induced by the in vivo exposure of 12-O-tetradecanoylphorbol-12-acetate, and in vitro exposure to LPS-activated macrophages. S. plebeian decreased the release of nitric oxide, cyclooxygenase-2 (COX-2), PGE2 and the expression of iNOS [63].

Bioactive constituents contained in S. miltiorrhiza such as the tanshinones and salvianolic acids have also been shown to have anti-inflammatory mechanisms by influencing cytokine production and iNOS activity. They also inhibited COX-2, hypoxia-inducible factor-1α, and nuclear factor κβ activity [64]. Moreover, in one study, tanshinones isolated from S. miltiorrhiza significantly inhibited the mRNA and protein expression of TNF-α, IL-1β, and IL-8 in LPS-stimulated macrophages [65]. Investigations into the constituents of Saliva plants have also confirmed that caffeic acid, rosmarinic acid [66] and ursolic acid [51] have strong anti-inflammatory properties.

3.6 Salvia and Antidepressant and Anxiolytic Effects

Depression and chronic stress can have deleterious effects on cognitive performance. In fact, cognitive deficits including impairments in memory, attention and learning are common symptoms of major depressive disorder and most anxiety disorders [67]. Exposure to chronic and acute stress can adversely affect cognitive abilities. Alzheimer’s disease also has a high comorbidity with major depression and it has been demonstrated that depressive symptoms can be a prodrome to this condition [68]. Interventions that have beneficial effects on depression and anxiety are therefore likely to have positive effects on cognitive performance.

The administration of hydroalcoholic extracts of S. elegans [69] and S. verticillata [70] has been shown to produce antidepressant and anxiolytic-like effects via animal models of depression and anxiety. The same has been observed following the administration of essential oils of S. sclarea [71, 72] and S. miltiorrhiza [73]. In fact, the effects of S. sclarea were more pronounced than those obtained from the administration of essential oils of Anthemis nobilis (chamomile), Rosmarinus officinalis (rosemary), and Lavandula angustifolia (lavender). The anti-stressor effect of S. sclarea was significantly blocked by pre-treatment with dopamine receptor antagonists, indicating its influences via dopaminergic activity [72]. Several constituents from S. officinalis also influence benzodiazepine receptor activity, including the flavones, apigenin, hispidulin and cirsimaritin; and the diterpenes, 7-methoxyrosmanol and galdosol [74].

The phenolic acids, rosmarinic acid and caffeic acid, also possess antidepressant and anxiolytic-like activity. In a neuropharmacological analysis, neither of these substances affected either the uptake of monoamines to synaptosomes or mitochondrial monoamine oxidase activity in the mouse brain, suggesting that they produce their antidepressant effects via mechanisms other than the inhibition of monoamine transporters and monoamine oxidase [75, 76]. Moreover, salvianolic acid B, a compound from S. miltiorrhiza [77], and salvinorin A from S. divinorum [78] exhibited antidepressant and anxiolytic effects in animals models.
Fig. 1

Major components in Salvia species and their pharmacodynamic effects in the brain

4 Human Trials on the Brain-Enhancing Effects of Salvia

The cognitive-enhancing efficacy of plants of genus Salvia has been investigated in several human trials and are summarised in Table 2. There have been two trials undertaken in patients with Alzheimer’s disease, both with preliminary, positive findings. In a pilot, open-label study, 11 patients with probable Alzheimer’s disease were administered capsules containing 50 µL of S. lavandulaefolia essential oil, administered 1–3 times per day over a 3-week period. Capsule intake was well tolerated, although two patients with a history of hypertension experienced increases in blood pressure at the highest dose. There were statistically significant reductions in caregiver-rated neuropsychiatric symptoms, and improvements in attention over the 6-week period, although these findings were tempered by the open-label, no-placebo arm, and small sample size [79]. In a randomised, double-blind, placebo-controlled study, the efficacy of an ethanolic extract of S. officinalis was evaluated in patients with Alzheimer’s disease. In this 4-month study, participants allocated to the active-drug condition (60 drops of S. officinalis daily) experienced significantly greater improvements in cognitive function as measured by the Alzheimer’s Disease Assessment Scale, and the Clinical Dementia Rating Scale. S. officinalis administration was well tolerated with no differences in adverse effects across the active and placebo conditions [80].
Table 2

Summary of human trials investigating the cognitive effects of plants of Salvia species

Study

Duration

Study design

Participants

Intervention

Main results

Alzheimer’s disease

 Akhondzadeh et al. [80]

4 months

Double-blind, placebo-controlled study

30 patients completed trial with average age of 72 years

S. officinalis extract 60 drops/day or placebo 60 drops/day. Salvia extract was prepared as 1:1 in alcohol 45%

Over a 4-month period, people taking Salvia liquid drops experienced significantly better cognitive function (as measured by the Alzheimer’s Disease Assessment Scale, and Clinical Dementia Rating Scale) compared with adults taking placebo capsules

 Perry et al. [79]

6 weeks

Open-label design

11 patients aged 76–95 years in whom a diagnosis of mild to moderate probable Alzheimer’s disease was established

Capsules contained 50 µL essential oil of S. lavandulaefolia plus 50 µL of sunflower oil

GC analysis demonstrated 94 peaks, the major peaks were of borneol, camphene, camphor, 1,8-cineole and α-terpineol, with only a trace of thujone. Dosage—Week 1: one capsule at 8 a.m.; Week 2: one capsule at 8 a.m. and one capsule at 7 p.m.; Weeks 3–6: as above with one additional capsule at 12:30 p.m.

There were statistically significant reductions in neuropsychiatric symptoms and an improvement in attention from baseline to 6 weeks

Acute cognitive and mood effects

 Tildesley et al. [82]

6 h

Double-blind, placebo-controlled study

Trial 1, 20 healthy adults with a mean age of 20 years; Trial 2, 24 healthy adults with a mean age of 23 years

In Trial 1, 20 participants received 50, 100 and 150 µL of a standardised essential oil extract of S. lavandulaefolia and placebo. In Trial 2, 24 participants received 25 and 50 µL of a standardised essential oil extract of S. lavandulaefolia and placebo

GC-MS was performed and the terpene constituents were as follows (%): α-pinene, 6.5; camphene, 6.3; β-pinene, 5.4; myrlene, 1.9; limonene, 1.2; 1,8-cineole, 25.8; camphor, 24.4; caryophyllene, 1.2; terpinen-4-OL, 2.0; borneol, 3.3; α-terpineol, 2.8

In Trial 1, memory performance was enhanced for the 50-µL dose at 1- and 2.5-hour time points. The effect was also apparent following administration of the 100 µL dose at 2.5 h post-dose sessions. A dose-specific enhancement on delayed word recall was also observed for the 50 µL dose at 1 and 2.5 h post-dose

In Trial 2, the immediate word recall effect at 1 hour was maintained, and this was coupled with improved memory performance at 4 h post-dose testing session for the same dose. No significant enhancement on either immediate or delayed word recall was found for either the lowest (25 µL) or the highest (150 µL) doses of Salvia

 Tildesley et al. [81]

6 h

Double-blind, placebo-controlled study

24 healthy adults with a mean age of 23 years

Two identical capsules corresponding to a dose of either 0 (a sunflower oil placebo), 25 µL, or 50 µL of S. lavandulaefolia essential oil in sunflower oil

Administration of S. lavandulaefolia resulted in a consistent improvement for both the 25- and 50-µL dose on the ‘Speed of Memory’ factor. There was also an improvement on the ‘Secondary Memory’ factor for the 25-µL dose. Mood was consistently enhanced, with increases in self-rated ‘alertness’, ‘calmness’ and ‘contentedness’ following the 50-µL dose and elevated ‘calmness’ following 25 µL

 Kennedy et al. [18]

4 h

Double-blind, placebo-controlled study

30 healthy adults with a mean age of 24 years

On each study day participants received 4 capsules of identical appearance, each containing either placebo or 150 mg of S. officinalis dried leaf. Drug dosages corresponded to either 0 mg (placebo), 300 or 600 mg of S. officinalis dried leaf

Both doses of Salvia led to improved ratings in mood in the absence of the stressor (that is, in pre-DISS mood scores) post-dose, with the lower dose reducing anxiety and the higher dose increasing ‘alertness’, ‘calmness’ and ‘contentedness’ on the Bond–Lader mood scales

The reduced anxiety effect following the lower dose was, however, abolished by performing the DISS, with the same dose also being associated with a reduction of alertness during performance. Task performance on the DISS battery was improved for the higher dose at both post-dose sessions, but reduced for the lower dose at the later testing session

 Scholey et al. [19]

6 h

Double-blind, placebo-controlled study

20 healthy, older-age adults with a mean age of 73 years

Each tablet contained either 167 or 333 mg of S. officinalis extract. Participants received oral doses of four pills, each combination of active and placebo pills corresponding to 0 (placebo), 167, 333, 666 or 1332 mg of the standardised sage extract depending on that day’s treatment

The S. officinalis for the study was a standardised ethanolic (70%) extract of dried S. officinalis in an approximate concentration ratio of 7.5:1 leaf/extract

Compared with the placebo condition, the 333-mg dose was associated with significant enhancement of secondary memory performance at all testing times. The same measure benefited to a lesser extent from other doses. There also were significant improvements to accuracy of attention following the 333-mg dose. In vitro analysis confirmed cholinesterase inhibiting properties for the extract

 Moss et al. [83]

Not specified

Randomised, single-blinded study

135 healthy adults with a mean age of 22 years

S. officinalis aroma, S. lavandulaefolia aroma and no aroma (control). Five drops of the appropriate essential oil and 5 mL water were placed on the stone and left to diffuse into the testing cubicle

S. officinalis aroma group performed significantly better than the control group on the quality of memory and secondary memory primary outcome factors from the test battery. The Alert mood measure displayed significant differences between both aromas and the control condition

 Kennedy et al. [22]

4 h

Double-blind, placebo-controlled study

36 healthy adults with a mean age of 24 years

A single soft gel capsule containing either 50 mL of S. lavandulaefolia essential oil plus olive oil, or a placebo capsule containing olive oil

The essential oil was a potent inhibitor of human AChE and consisted almost exclusively of monoterpenoids. Oral consumption led to improved performance of secondary memory and attention tasks, most notably at the 1-hour post-dose testing session, and reduced mental fatigue and increased alertness, which were more pronounced 4-hours post-dose

AChE acetylcholinesterase, DISS Daytime Insomnia Symptom Scale, GC gas chromatography, GC-MS gas chromatography-mass spectrometry

The cognitive-enhancing effects of acute, single administration of different Salvia species has been investigated in six studies, five utilising randomised, double-blind, placebo-controlled designs. In five studies, the efficacy of Salvia plants in healthy young adults was investigated, while one was conducted on healthy, older-age volunteers. Positive cognitive (e.g. secondary memory, attention, word recall and speed of memory) and mood-enhancing (e.g. alertness, calmness and contentedness) effects from the single administration of differing dosages of essential oil of S. lavandulaefolia in healthy adults was demonstrated [22, 81, 82]. Improvements in mood (e.g. alertness, contentedness, and calmness) and cognition were also identified following the single administration of a S. officinalis extract to healthy young adults [18], and enhancement in memory and attention were revealed following the single administration of S. officinalis to healthy, older-age adults [19]. In a randomised, single-blinded design (participant-masked), Moss et al. [83] also found positive cognitive and mood-enhancing effects from acute exposure to the aroma of S. officinalis and S. lavandulaefolia.

These studies provide preliminary support for the cognitive and mood-enhancing efficacy of some Salvia species. However, conclusions are tempered by the small sample sizes and short treatment duration. Treatment dose, Salvia species and extracts used have been variable, further limiting study conclusions. Additional research is required utilising larger populations, particularly in examining its efficacy for the treatment of patients with Alzheimer’s disease. Furthermore, although Salvia seems to have positive, acute, cognitive-enhancing effects, its effects over longer-term ingestion require investigation.

5 Factors Influencing Biological Potency of Salvia

Although the influence of plants of different species of Salvia on cognition has been reviewed, differences in the active constituents across each species are likely to affect their influence on biological processes and therefore their therapeutic efficacy. Currently, the relative efficacy of different Salvia species on cognitive function is unknown. The influence of individual constituents also requires further investigation. Moreover, human studies on cognitive function have only been conducted using S. officinalis and S. lavandulaefolia. The extracts used also varied considerably as both essential oils and ethanolic extracts were examined.

Typical factors influencing the potency of herbal remedies include growing, harvesting, collection, drying, and extraction methods used. This requires consideration when evaluating the therapeutic efficacy of Salvia plants. For example, in an examination of the antioxidant capacity of S. officinalis, it was found that methanolic extract yielded the highest total phenolic compounds and antioxidant activity compared with aqueous and ethanol extracts [84]. An evaluation of antioxidant potential of 10 Salvia species demonstrated that ethanol extracts possessed significantly higher antioxidant capacity and total phenolic content compared with aqueous and CO2 extraction [45]. Ratios of amount-to-solvent, solvent temperature and duration of immersion also influence extract potency [85]. Even the season of Salvia plant collection is important as the highest content of rosmarinic acid in S. officinalis leaves was detected when collections occurred in May, July and September [86].

6 Contraindications for the Use of Salvia

The acute administration of Salvia in healthy adults has confirmed that its single intake is well tolerated, with no reported adverse events. The safety profile of Salvia plants in longer-term, human trials are summarised in Table 3. Overall, all administered Salvia species were well tolerated, with only minor adverse events reported. Populations examined included patients with Alzheimer’ disease, menopausal women suffering from hot flushes, older-age men undergoing treatment for prostate cancer and suffering from hot flushes, male and female adults with type 2 diabetes mellitus, and male and female patients with newly diagnosed primary hyperlipidaemia. Adverse events reported across all studies comprising approximately 140 adult participants taking different Salvia extracts included increased blood pressure in two patients with Alzheimer’s disease and a history of hypertension (essential oil of S. lavandulaefolia), infrequent reports of mild gastrointestinal complaints (S. officinalis and S. spissum, extraction process not detailed), and one event of acneiform skin eruption (S. officinalis, extraction process not detailed).
Table 3

Safety of Saliva plant administration in chronic human trials

Study

Study design

Population

Salvia treatment

Adverse events

Akhondzadeh et al. [80]

4-month, double-blind, placebo-controlled study

30 patients with Alzheimer’s disease with an average age of 72 years

Ethanolic extract of S. officinalis, 60 drops daily

No difference in adverse events between Salvia and placebo conditions over the 4-month trial, except for near-statistically significant reductions in agitation (p = 0.09) in Salvia-treated patients

Perry et al. [79]

6-week, open-label design

11 patients aged 76–95 years with probable Alzheimer’s disease

50 µL essential oil of S. lavandulaefolia, titrated to 3 capsules daily over 3 weeks

Increased blood pressure in two patients with a history of hypertension

Bommer et al. [89]

8-week, open-label design

69 women aged between 50 and 65 years (mean age 56 years), at least 12 months since last menstruation, at least five hot flushes daily

Once daily, 280-mg S. spissum tablet. Extract was thujone-free. Extraction process not detailed

10 adverse events among 6 patients, of which 2 were related to study medication (mild abdominal pain and mild diarrhoea in one patient)

Vandecasteele et al. [90]

8-week, open-label design

10 prostate cancer patients (median age 68) receiving androgen deprivation therapy and experiencing hot flashes

One 150-mg S. officinalis capsule, 3 times daily. Extract was thujone-free. Extraction process not detailed

Non-significant decrease in luteinising hormone and follicular stimulating hormone. One patient experienced acneiform skin eruption after 6 weeks on Salvia. Causal connection with sage could not be ruled out

Behradmanesh et al. [91]

12-week, double-blind, placebo-controlled study

80 type II diabetic patients (average age 52 years) who had not reached the ideal control of the disease

One, 150-mg S. officinalis tablet, 3 times daily. Extraction process not detailed

2 patients on active treatment reported mild gastrointestinal complaints, but did not require withdrawal from study

Kianbakht et al. [92]

8-week, double-blind, placebo-controlled study

67 patients aged 20–60 years with newly diagnosed primary hyperlipidaemia

One, 500-mg ethanolic/aqueous extract of S. officinalis tablet, 3 times daily

No reported adverse events

The essential oils of Salvia plants do contain varying concentrations of α and β-thujone [87]. In animal studies it has been confirmed that thujone can be neurotoxic by inhibiting the γ-aminobutyric acid A (GABAA) receptor, causing excitation and convulsions in a dose-dependent manner. Although its effect in humans is uncertain, cases of severe intoxication in humans have been reported after consumption of essential oils rich in thujone [87]. Consequently, the Committee on Herbal Medicinal Products/European Medicines Agency (HMPC/EMA) has recommended an upper daily thujone intake of 6 mg derived from products used for medicinal purposes [88].

7 Conclusion and Directions for Future Research

Salvia plants have historically been used for the treatment of several ailments, with traditional knowledge suggesting they have benefits for cognitive and neurological conditions. From this review it seems that the knowledge passed on by our ancestors may have merit. Findings from research confirm that many Salvia species and their individual active constituents influence several biological processes that may impact on neurological and cognitive function. In vitro, animal and preliminary human studies have supported the evidence of Salvia plants to enhance cognitive skills and guard against neurodegenerative disorders. However, further research is required in several areas.

Presently, the majority of human studies have used S. officinalis and S. lavandulaefolia species, so the efficacy of other Salvia species is uncertain. Moreover, the extracts used have varied considerably across studies. Ethanolic, methanolic and aqueous extracts have been used, along with the essential oils of S. officinalis and S. lavandulaefolia. The potency and pharmacodynamic effects of these differing extracts are likely to vary considerably, potentially impacting on their therapeutic efficacy. This is a matter that requires consideration in research as the extracts used are likely to influence outcomes. A common issue in herbal medicine relates to differences in the quality of extracts, making generalised conclusions about a medicinal herb difficult. It is important that standardised, replicable extracts be developed that include some measure of potency and purity.

Although there have been two studies conducted on patients with Alzheimer’s disease for a period up to 3 months, the majority of research has evaluated the efficacy of a single administration of Salvia plants. The efficacy of longer term intake of different Salvia species on cognition therefore requires examination. Larger scale clinical studies are also essential, particularly given the initial promising findings in Alzheimer’s disease.

Several species of Salvia are commonly ingested across numerous cultures, which increases confidence about its safety. However, further confirmation about its safety is necessary, particularly when ingested at higher doses. Given the potential of neurotoxic effects from the Salvia constituent thujone, further investigation is warranted, and/or extracts containing little or no thujone may be prudent.

Overall, evidence for the cognitive-enhancing and protective effects of Salvia plants is promising. However, greater investigation is essential to help us elucidate the potential of this commonly ingested herb to enhance cognitive health and wellbeing.

Notes

Acknowledgements

The gracious help from Stephen J. Smith with the proofing of this article is acknowledged.

Compliance with Ethical Standards

Adrian Lopresti has no conflicts of interest that are directly relevant to the content of this manuscript. No funding was received in the preparation of this review.

References

  1. 1.
    Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999;51(5):527–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Lu Y, Foo LY. Polyphenolics of Salvia—a review. Phytochemistry. 2002;59(2):117–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Shekarchi M, Hajimehdipoor H, Saeidnia S, Gohari AR, Hamedani MP. Comparative study of rosmarinic acid content in some plants of Labiatae family. Pharmacogn Mag. 2012;8(29):37–41.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Leung AY, Foster S. Encyclopaedia of common natural ingredients. Chichester: Wiley; 1996.Google Scholar
  5. 5.
    Zhang Y, Jiang P, Ye M, Kim SH, Jiang C, Lu J. Tanshinones: sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci. 2012;13(10):13621–66.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    More SV, Kumar H, Cho DY, Yun YS, Choi DK. Toxin-induced experimental models of learning and memory impairment. Int J Mol Sci. 2016;17(9).doi: 10.3390/ijms17091447.
  7. 7.
    Teng Y, Zhang MQ, Wang W, Liu LT, Zhou LM, Miao SK, et al. Compound danshen tablet ameliorated abeta25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins. BMC Complement Altern Med. 2014;14:23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jiang P, Li C, Xiang Z, Jiao B. Tanshinone IIA reduces the risk of Alzheimer’s disease by inhibiting iNOS, MMP2 and NFkappaBp65 transcription and translation in the temporal lobes of rat models of Alzheimer’s disease. Mol Med Rep. 2014;10(2):689–94.PubMedGoogle Scholar
  9. 9.
    Khodagholi F, Ashabi G. Dietary supplementation with Salvia sahendica attenuates memory deficits, modulates CREB and its down-stream molecules and decreases apoptosis in amyloid beta-injected rats. Behav Brain Res. 2013;15(241):62–9.CrossRefGoogle Scholar
  10. 10.
    Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res. 2007;180(2):139–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee YW, Kim DH, Jeon SJ, Park SJ, Kim JM, Jung JM, et al. Neuroprotective effects of salvianolic acid B on an Abeta25-35 peptide-induced mouse model of Alzheimer’s disease. Eur J Pharmacol. 2013;704(1–3):70–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Rasoolijazi H, Azad N, Joghataei MT, Kerdari M, Nikbakht F, Soleimani M. The protective role of carnosic acid against beta-amyloid toxicity in rats. SciWorldJ. 2013;2013:917082.Google Scholar
  13. 13.
    Patil CS, Singh VP, Satyanarayan PS, Jain NK, Singh A, Kulkarni SK. Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology. 2003;69(2):59–67.CrossRefPubMedGoogle Scholar
  14. 14.
    Luchicchi A, Bloem B, Viana JN, Mansvelder HD, Role LW. Illuminating the role of cholinergic signaling in circuits of attention and emotionally salient behaviors. Front Synaptic Neurosci. 2014;6:24.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Klinkenberg I, Sambeth A, Blokland A. Acetylcholine and attention. Behav Brain Res. 2011;221(2):430–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Smach MA, Hafsa J, Charfeddine B, Dridi H, Limem K. Effects of sage extract on memory performance in mice and acetylcholinesterase activity. Ann Pharm Fr. 2015;73(4):281–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Kennedy DO, Pace S, Haskell C, Okello EJ, Milne A, Scholey AB. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology. 2006;31(4):845–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Scholey AB, Tildesley NT, Ballard CG, Wesnes KA, Tasker A, Perry EK, et al. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl). 2008;198(1):127–39.CrossRefPubMedGoogle Scholar
  20. 20.
    Foolad F, Khodagholi F. Dietary supplementation with Salvia sahendica attenuates acetylcholinesterase activity and increases mitochondrial transcription factor A and antioxidant proteins in the hippocampus of amyloid beta-injected rats. J Pharm Pharmacol. 2013;65(10):1555–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Senol FS, Orhan IE, Erdem SA, Kartal M, Sener B, Kan Y, et al. Evaluation of cholinesterase inhibitory and antioxidant activities of wild and cultivated samples of sage (Salvia fruticosa) by activity-guided fractionation. J Med Food. 2011;14(11):1476–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Kennedy DO, Dodd FL, Robertson BC, Okello EJ, Reay JL, Scholey AB, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol. 2011;25(8):1088–100.CrossRefPubMedGoogle Scholar
  23. 23.
    Sallam A, Mira A, Ashour A, Shimizu K. Acetylcholine esterase inhibitors and melanin synthesis inhibitors from Salvia officinalis. Phytomedicine. 2016;23(10):1005–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Merad M, Soufi W, Ghalem S, Boukli F, Baig MH, Ahmad K, et al. Molecular interaction of acetylcholinesterase with carnosic acid derivatives: a neuroinformatics study. CNS Neurol Disord Drug Targets. 2014;13(3):440–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Marcelo F, Dias C, Martins A, Madeira PJ, Jorge T, Florencio MH, et al. Molecular recognition of rosmarinic acid from Salvia sclareoides extracts by acetylcholinesterase: a new binding site detected by NMR spectroscopy. Chemistry. 2013;19(21):6641–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Xu QQ, Xu YJ, Yang C, Tang Y, Li L, Cai HB, et al. Sodium Tanshinone IIA sulfonate attenuates scopolamine-induced cognitive dysfunctions via improving cholinergic system. Biomed Res Int. 2016;2016:9852536.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhou Y, Li W, Xu L, Chen L. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ Toxicol Pharmacol. 2011;31(3):443–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Bowling H, Bhattacharya A, Klann E, Chao MV. Deconstructing brain-derived neurotrophic factor actions in adult brain circuits to bridge an existing informational gap in neuro-cell biology. Neural Regen Res. 2016;11(3):363–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Qin XY, Cao C, Cawley NX, Liu TT, Yuan J, Loh YP, et al. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N = 7277). Mol Psychiatry. 2016. doi: 10.1038/mp.2016.62.PubMedCentralGoogle Scholar
  31. 31.
    Fonteles AA, de Souza CM, de Sousa Neves JC, Menezes AP, Santos do Carmo MR, Fernandes FD, et al. Rosmarinic acid prevents against memory deficits in ischemic mice. Behav Brain Res. 2016;15(297):91–103.CrossRefGoogle Scholar
  32. 32.
    Jin X, Liu P, Yang F, Zhang YH, Miao D. Rosmarinic acid ameliorates depressive-like behaviors in a rat model of CUS and Up-regulates BDNF levels in the hippocampus and hippocampal-derived astrocytes. Neurochem Res. 2013;38(9):1828–37.CrossRefPubMedGoogle Scholar
  33. 33.
    Takeda H, Tsuji M, Yamada T, Masuya J, Matsushita K, Tahara M, et al. Caffeic acid attenuates the decrease in cortical BDNF mRNA expression induced by exposure to forced swimming stress in mice. Eur J Pharmacol. 2006;534(1–3):115–21.CrossRefPubMedGoogle Scholar
  34. 34.
    Xu SL, Bi CW, Choi RC, Zhu KY, Miernisha A, Dong TT, et al. Flavonoids induce the synthesis and secretion of neurotrophic factors in cultured rat astrocytes: a signaling response mediated by estrogen receptor. Evid Based Complement Alternat Med. 2013;2013:127075.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Yao RQ, Qi DS, Yu HL, Liu J, Yang LH, Wu XX. Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway. Neurochem Res. 2012;37(12):2777–86.CrossRefPubMedGoogle Scholar
  36. 36.
    Kosaka K, Yokoi T. Carnosic acid, a component of rosemary (Rosmarinus officinalis L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells. Biol Pharm Bull. 2003;26(11):1620–2.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhao Y, Xu P, Hu S, Du L, Xu Z, Zhang H, et al. Tanshinone II A, a multiple target neuroprotectant, promotes caveolae-dependent neuronal differentiation. Eur J Pharmacol. 2015;15(765):437–46.CrossRefGoogle Scholar
  38. 38.
    Wang W, Huang CY, Tsai FJ, Tsai CC, Yao CH, Chen YS. Growth-promoting effects of quercetin on peripheral nerves in rats. Int J Artif Organs. 2011;34(11):1095–105.CrossRefPubMedGoogle Scholar
  39. 39.
    Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, et al. Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis. 2013;59:100–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Sita G, Hrelia P, Tarozzi A, Morroni F. Isothiocyanates are promising compounds against oxidative stress, neuroinflammation and cell death that may benefit neurodegeneration in Parkinson’s Disease. Int J Mol Sci. 2016;17(9). doi: 10.3390/ijms17091454.
  41. 41.
    Liu T, Zhong S, Liao X, Chen J, He T, Lai S, et al. A meta-analysis of oxidative stress markers in depression. PLoS One. 2015;10(10):e0138904.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lopresti AL. Oxidative and nitrosative stress in ADHD: possible causes and the potential of antioxidant-targeted therapies. Atten Defic Hyperact Disord. 2015;7(4):237–47.CrossRefPubMedGoogle Scholar
  43. 43.
    Yabuki Y, Fukunaga K. Oral administration of glutathione improves memory deficits following transient brain ischemia by reducing brain oxidative stress. Neuroscience. 2013;10(250):394–407.CrossRefGoogle Scholar
  44. 44.
    Hritcu L, Ciobica A, Stefan M, Mihasan M, Palamiuc L, Nabeshima T. Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson’s disease. Neurosci Res. 2011;71(1):35–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Sulniute V, Ragazinskiene O, Venskutonis PR. Comprehensive evaluation of antioxidant potential of 10 salvia species using high pressure methods for the isolation of lipophilic and hydrophilic plant fractions. Plant Foods Hum Nutr. 2016;71(1):64–71.CrossRefPubMedGoogle Scholar
  46. 46.
    Chang CC, Chang YC, Hu WL, Hung YC. Oxidative stress and salvia miltiorrhiza in aging-associated cardiovascular diseases. Oxid Med Cell Longev. 2016;2016:4797102.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Hasanein P, Felehgari Z, Emamjomeh A. Preventive effects of Salvia officinalis L. against learning and memory deficit induced by diabetes in rats: Possible hypoglycaemic and antioxidant mechanisms. Neurosci Lett. 2016;27(622):72–7.CrossRefGoogle Scholar
  48. 48.
    Lu Y, Foo Y. Antioxidant activities of polyphenols from sage (Salvia officinalis). Food Chem. 2001;75:197–202.CrossRefGoogle Scholar
  49. 49.
    Lu Y, Foo Y. Salvianolic acid L, a potent phenolic antioxidant from Salvia officinalis. Tetrahedron Lett. 2001;42:8223–5.CrossRefGoogle Scholar
  50. 50.
    Porres-Martinez M, Gonzalez-Burgos E, Carretero ME, Gomez-Serranillos MP. Major selected monoterpenes alpha-pinene and 1,8-cineole found in Salvia lavandulifolia (Spanish sage) essential oil as regulators of cellular redox balance. Pharm Biol. 2015;53(6):921–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): a metabolite with promising therapeutic potential. Life Sci. 2016;1(146):201–13.CrossRefGoogle Scholar
  52. 52.
    Birtic S, Dussort P, Pierre FX, Bily AC, Roller M. Carnosic acid. Phytochemistry. 2015;115:9–19.CrossRefPubMedGoogle Scholar
  53. 53.
    Boitard C, Cavaroc A, Sauvant J, Aubert A, Castanon N, Laye S, et al. Impairment of hippocampal-dependent memory induced by juvenile high-fat diet intake is associated with enhanced hippocampal inflammation in rats. Brain Behav Immun. 2014;40:9–17.CrossRefPubMedGoogle Scholar
  54. 54.
    Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut. 2011;60(3):307–17.CrossRefPubMedGoogle Scholar
  55. 55.
    Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433–40.CrossRefPubMedGoogle Scholar
  56. 56.
    Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctot KL. Inflammatory markers in mild cognitive impairment: a meta-analysis. J Alzheimers Dis. 2015;47(3):669–79.CrossRefPubMedGoogle Scholar
  57. 57.
    Verlaet AA, Noriega DB, Hermans N, Savelkoul HF. Nutrition, immunological mechanisms and dietary immunomodulation in ADHD. Eur Child Adolesc Psychiatry. 2014;23(7):519–29.CrossRefPubMedGoogle Scholar
  58. 58.
    Goldsmith DR, Haroon E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD, et al. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behav Immun. 2016;56:281–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Johnsen E, Fathian F, Kroken RA, Steen VM, Jorgensen HA, Gjestad R, et al. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry. 2016;16:60.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Abu-Darwish MS, Cabral C, Ferreira IV, Goncalves MJ, Cavaleiro C, Cruz MT, et al. Essential oil of common sage (Salvia officinalis L.) from Jordan: assessment of safety in mammalian cells and its antifungal and anti-inflammatory potential. Biomed Res Int. 2013;538940.Google Scholar
  61. 61.
    Oniga I, Parvu AE, Toiu A, Benedec D. Effects of Salvia officinalis L. extract on experimental acute inflammation. Rev Med Chir Soc Med Nat Iasi. 2007;111(1):290–4.PubMedGoogle Scholar
  62. 62.
    Schwager J, Richard N, Fowler A, Seifert N, Raederstorff D. Carnosol and related substances modulate chemokine and cytokine production in macrophages and chondrocytes. Molecules. 2016;21(4):465.CrossRefPubMedGoogle Scholar
  63. 63.
    Akram M, Syed AS, Kim KA, Lee JS, Chang SY, Kim CY, et al. Heme oxygenase 1-mediated novel anti-inflammatory activities of Salvia plebeia and its active components. J Ethnopharmacol. 2015;4(174):322–30.CrossRefGoogle Scholar
  64. 64.
    Bonaccini L, Karioti A, Bergonzi MC, Bilia AR. Effects of salvia miltiorrhiza on CNS neuronal injury and degeneration: a plausible complementary role of tanshinones and depsides. Planta Med. 2015;81(12–13):1003–16.PubMedGoogle Scholar
  65. 65.
    Ma S, Zhang D, Lou H, Sun L, Ji J. Evaluation of the anti-inflammatory activities of tanshinones isolated from Salvia miltiorrhiza var. alba roots in THP-1 macrophages. J Ethnopharmacol. 2016;21(188):193–9.CrossRefGoogle Scholar
  66. 66.
    Nabavi SF, Tenore GC, Daglia M, Tundis R, Loizzo MR, Nabavi SM. The cellular protective effects of rosmarinic acid: from bench to bedside. Curr Neurovasc Res. 2015;12(1):98–105.CrossRefPubMedGoogle Scholar
  67. 67.
    Scult MA, Paulli AR, Mazure ES, Moffitt TE, Hariri AR, Strauman TJ. The association between cognitive function and subsequent depression: a systematic review and meta-analysis. Psychol Med. 2016;14:1–17.Google Scholar
  68. 68.
    Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas. 2014;79(2):184–90.CrossRefPubMedGoogle Scholar
  69. 69.
    Herrera-Ruiz M, Garcia-Beltran Y, Mora S, Diaz-Veliz G, Viana GS, Tortoriello J, et al. Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans. J Ethnopharmacol. 2006;107(1):53–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Naderi N, Akhavan N, Aziz Ahari F, Zamani N, Kamalinejad M, Shokrzadeh M, et al. Effects of hydroalcoholic extract from salvia verticillata on pharmacological models of seizure, anxiety and depression in mice. Iran J Pharm Res. 2011 Summer;10(3):535–45.Google Scholar
  71. 71.
    Gross M, Nesher E, Tikhonov T, Raz O, Pinhasov A. Chronic food administration of Salvia sclarea oil reduces animals’ anxious and dominant behavior. J Med Food. 2013;16(3):216–22.CrossRefPubMedGoogle Scholar
  72. 72.
    Seol GH, Shim HS, Kim PJ, Moon HK, Lee KH, Shim I, et al. Antidepressant-like effect of Salvia sclarea is explained by modulation of dopamine activities in rats. J Ethnopharmacol. 2010;130(1):187–90.CrossRefPubMedGoogle Scholar
  73. 73.
    Liu AD, Cai GH, Wei YY, Yu JP, Chen J, Yang J, et al. Anxiolytic effect of essential oils of Salvia miltiorrhiza in rats. Int J Clin Exp Med. 2015;8(8):12756–64.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Kavvadias D, Monschein V, Sand P, Riederer P, Schreier P. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med. 2003;69(2):113–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Takeda H, Tsuji M, Inazu M, Egashira T, Matsumiya T. Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. Eur J Pharmacol. 2002;449(3):261–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Pereira P, Tysca D, Oliveira P, da Silva Brum LF, Picada JN, Ardenghi P. Neurobehavioral and genotoxic aspects of rosmarinic acid. Pharmacol Res. 2005;52(3):199–203.CrossRefPubMedGoogle Scholar
  77. 77.
    Feng Y, You Z, Yan S, He G, Chen Y, Gou X, et al. Antidepressant-like effects of salvianolic acid B in the mouse forced swim and tail suspension tests. Life Sci. 2012;90(25–26):1010–4.CrossRefPubMedGoogle Scholar
  78. 78.
    Braida D, Capurro V, Zani A, Rubino T, Vigano D, Parolaro D, et al. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol. 2009;157(5):844–53.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav. 2003;75(3):651–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003;28(1):53–9.CrossRefPubMedGoogle Scholar
  81. 81.
    Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav. 2005;83(5):699–709.CrossRefPubMedGoogle Scholar
  82. 82.
    Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, et al. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav. 2003;75(3):669–74.CrossRefPubMedGoogle Scholar
  83. 83.
    Moss L, Rouse M, Wesnes KA, Moss M. Differential effects of the aromas of Salvia species on memory and mood. Hum Psychopharmacol. 2010;25(5):388–96.CrossRefPubMedGoogle Scholar
  84. 84.
    Pop AV, Tofana M, Socaci SA, Varban D, Nagy M, Bors M, et al. Evaluation of antioxidant activity and phenolic content in different Salvia officinalis L. extracts. Bull UASVM Food Sci Technol. 2015;72(2):210–4.Google Scholar
  85. 85.
    Dent M, Dragovi-Uzelac V, Penic M, Brncic M, Bosiljkov T, Levaj B. The effect of extraction solvents, temperature and time on the composition and mass fraction of polyphenols in dalmatian wild sage (Salvia officinalis L.) Extracts Food Technol Biotechnol. 2013;51(1):84–91.Google Scholar
  86. 86.
    Gird CE, Nencu I, Costea T, Dutu LE, Popescu ML, Ciupitu N. Quantitative analysis of phenolic compounds from Salvia officinalis L. leaves. Farmacia. 2014;62(4):649–57.Google Scholar
  87. 87.
    Pelkonen O, Abass K, Wiesner J. Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment. Regul Toxicol Pharmacol. 2013;65(1):100–7.CrossRefPubMedGoogle Scholar
  88. 88.
    EMA/HMPC. Public statement on the use of herbal medicinal products containing thujone. 2011 [cited; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/02/WC500102294.pdf.
  89. 89.
    Bommer S, Klein P, Suter A. First time proof of sage's tolerability and efficacy in menopausal women with hot flushes. Adv Ther. 2011;28:490–500.CrossRefPubMedGoogle Scholar
  90. 90.
    Vandecasteele K, Ost P, Oosterlinck W, et al. Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. Phytother Res. 2012;26:208–13.CrossRefPubMedGoogle Scholar
  91. 91.
    Behradmanesh S, Derees F, Rafieian-Kopaei M. Effect of Salvia officinalis on diabetic patients. J Renal Inj Prev. 2013;2:51–4.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Kianbakht S, Abasi B, Perham M, et al. Antihyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double-blind placebo-controlled clinical trial. Phytother Res. 2011;25:1849–53.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.School of Psychology and Exercise ScienceMurdoch UniversityPerthAustralia

Personalised recommendations